Blood-brain barrier in drug discovery : optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs / edited by Li Di, Edward H. Kerns.

Contributor(s): Di, Li [editor.] | Kerns, Edward Harvel [editor.]Material type: TextTextPublisher: Hoboken, New Jersey : John Wiley & Sons Inc., [2015]Copyright date: 2015Description: 1 online resource (607 pages) : illustrations (some color)Content type: text Media type: computer Carrier type: online resourceISBN: 9781118788547Subject(s): Brain -- Effect of drugs on | Blood-brain barrierGenre/Form: Electronic books.Additional physical formats: Print version:: Blood-brain barrier in drug discovery : optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs.DDC classification: 615.7/8 LOC classification: RM315 | .B56 2015Online resources: Click to View
Contents:
Machine generated contents note: Summary List of Chapters1. Overview/Introduction / Li Di (Pfizer Inc.), Edward H. Kerns (Pharmacokinetics of Brain Exposure)2. Pharmacokinetics of CNS penetration / Andreas Reichel (Bayer)3. Free Drug Hyposthesis for CNS Drug Candidates / Xingrong Liu (Genentech)4. Species Differences and impact of desease state on BBB / Jean-Marie Nicolas (UCB Pharma S.A.)Mechanisms of Drugs Across the Blood-Brain Barrier5. Passive diffusion permeability of the BBB - examples and SAR / Phil Jeffrey (GSK)6. Efflux transport at the BBB - examples and SAR / Jerome Hochman (Merck)7. Uptake transport at the BBB - examples and SAR / Zack Cheng (AstraZeneca)8. Uptake of proteins and antibodies at the BBB / William Pardridge (UCLA)Predicting and Measuring Brain Exposure of Drugs9. In silico tools for assessing brain exposure / Hongming Chen (AstraZeneca)10. In vitro assays for assessing BBB permeability - vascular cells, artificial membranes, brain slice, cell uptake / Winfried Neuhaus (University of Vienna)11. Human-based in vitro endothelial cell models / Eric Shusta (University of Wisconsin)12. In vitro assays for assessing brain binding / Li Di (Pfizer)13. In vivo studies of brain exposure / Edward H. Kerns14. PBPK models for BBB / Elizabeth de Lange (Leiden University)15. PK/PD modeling of CNS drug candidates / Johan Gabrielsson (Swedish University)16. Microdialysis to assess free drug concentration in brain / William Kielbasa (Lilly)17. Imaging technique for CNS drug discovery / Lei Zhang (Pfizer Inc.)Modulating Brain Penetration of Leads During Drug Discovery18. Designing CNS drugs for optimal brain exposure / Zoran Rankovic (Lilly)19. Case studies of CNS drug optimization - medicinal chemistry and CNS biology perspectives / Kevin J. Hodgetts (Harvard NeuroDiscovery Center)20. Designing peripheral drugs for minimal brain exposue / Peter Bungay (Pfizer)21. Case studies of non-CNS drugs to minimize brain penetration - Nonsudative antihistamines / Andrew Crowe (Curtin University)Case Studies in CNS Drug Discovery22. Case study 1 on discovery of a successful CNS drug - Fycompa (AMPA Receptor Antagonist) / Andrew Satlin and Antonio Laurenza (Eisai)23. Case study 2 on discovery of a successful CNS drug - Vortioxetine (Serotonin Modulator and Stimulator) / Benny Bang-Andersen (Lundbeck)Drug Delivery Techniques to CNS24. Brain delivery using nanotechnology / Xinguo Jiang (Fudan University)25. Intranasal delivery to CNS / Lisbeth Illum (University of Nottingham)Future Prospective in Blood Brain Barrier Advancement26. Conclusion Remarks / Joan Abbott (King's College).
Summary: "Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide practical solutions to increase brain penetration or minimize CNS side-effects. Reviews state-of-the-art in silico, in vitro, and in vivo tools to assess brain penetration and advanced CNS drug delivery strategies. Covers BBB physiology, medicinal chemistry design principles, free drug hypothesis for the BBB, and transport mechanisms including passive diffusion, uptake/efflux transporters, and receptor-mediated processes. Highlights the advances in modelling BBB pharmacokinetics and dynamics relationships (PK/PD) and physiologically-based pharmacokinetics (PBPK). Discusses case studies of successful CNS and non-CNS drugs, lessons learned and paths to the market"--Provided by publisher.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Includes bibliographical references and index.

Machine generated contents note: Summary List of Chapters1. Overview/Introduction / Li Di (Pfizer Inc.), Edward H. Kerns (Pharmacokinetics of Brain Exposure)2. Pharmacokinetics of CNS penetration / Andreas Reichel (Bayer)3. Free Drug Hyposthesis for CNS Drug Candidates / Xingrong Liu (Genentech)4. Species Differences and impact of desease state on BBB / Jean-Marie Nicolas (UCB Pharma S.A.)Mechanisms of Drugs Across the Blood-Brain Barrier5. Passive diffusion permeability of the BBB - examples and SAR / Phil Jeffrey (GSK)6. Efflux transport at the BBB - examples and SAR / Jerome Hochman (Merck)7. Uptake transport at the BBB - examples and SAR / Zack Cheng (AstraZeneca)8. Uptake of proteins and antibodies at the BBB / William Pardridge (UCLA)Predicting and Measuring Brain Exposure of Drugs9. In silico tools for assessing brain exposure / Hongming Chen (AstraZeneca)10. In vitro assays for assessing BBB permeability - vascular cells, artificial membranes, brain slice, cell uptake / Winfried Neuhaus (University of Vienna)11. Human-based in vitro endothelial cell models / Eric Shusta (University of Wisconsin)12. In vitro assays for assessing brain binding / Li Di (Pfizer)13. In vivo studies of brain exposure / Edward H. Kerns14. PBPK models for BBB / Elizabeth de Lange (Leiden University)15. PK/PD modeling of CNS drug candidates / Johan Gabrielsson (Swedish University)16. Microdialysis to assess free drug concentration in brain / William Kielbasa (Lilly)17. Imaging technique for CNS drug discovery / Lei Zhang (Pfizer Inc.)Modulating Brain Penetration of Leads During Drug Discovery18. Designing CNS drugs for optimal brain exposure / Zoran Rankovic (Lilly)19. Case studies of CNS drug optimization - medicinal chemistry and CNS biology perspectives / Kevin J. Hodgetts (Harvard NeuroDiscovery Center)20. Designing peripheral drugs for minimal brain exposue / Peter Bungay (Pfizer)21. Case studies of non-CNS drugs to minimize brain penetration - Nonsudative antihistamines / Andrew Crowe (Curtin University)Case Studies in CNS Drug Discovery22. Case study 1 on discovery of a successful CNS drug - Fycompa (AMPA Receptor Antagonist) / Andrew Satlin and Antonio Laurenza (Eisai)23. Case study 2 on discovery of a successful CNS drug - Vortioxetine (Serotonin Modulator and Stimulator) / Benny Bang-Andersen (Lundbeck)Drug Delivery Techniques to CNS24. Brain delivery using nanotechnology / Xinguo Jiang (Fudan University)25. Intranasal delivery to CNS / Lisbeth Illum (University of Nottingham)Future Prospective in Blood Brain Barrier Advancement26. Conclusion Remarks / Joan Abbott (King's College).

"Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide practical solutions to increase brain penetration or minimize CNS side-effects. Reviews state-of-the-art in silico, in vitro, and in vivo tools to assess brain penetration and advanced CNS drug delivery strategies. Covers BBB physiology, medicinal chemistry design principles, free drug hypothesis for the BBB, and transport mechanisms including passive diffusion, uptake/efflux transporters, and receptor-mediated processes. Highlights the advances in modelling BBB pharmacokinetics and dynamics relationships (PK/PD) and physiologically-based pharmacokinetics (PBPK). Discusses case studies of successful CNS and non-CNS drugs, lessons learned and paths to the market"--Provided by publisher.

Description based on print version record.

Electronic reproduction. Ann Arbor, MI : ProQuest, 2015. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries.

There are no comments on this title.

to post a comment.